his resume

Dr Grosset Christophe, PhD, 48 year old
DR2 INSERM
Address:
Inserm U1035, Biotherapy of Genetic, Inflammatory diseases and of Cancer (Head: Pr Alain Taïeb),
University of Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France.
Phone: (+33) 557574630; Fax: (+33) 557571374; Email: [email protected]
Education:
- Jan. 1998: PhD. Cellular and Molecular Biology, UMR CNRS 5540, University of Bordeaux, France.
- Oct. 2011: HDR Accreditation to supervise research, University of Bordeaux, France.
Professional Experience:
- 1998-2000: Postdoctoral fellow in Ann-Bin Shyu’s lab; Department of Biochemistry and Molecular
Biology, The Texas Houston Medical School, Houston, Texas, USA.
- 2000-2002: Postdoctoral fellow in Jean Ripoche’s team, Laboratoire de Greffe de Moelle, UMR
CNRS 5540, University of Bordeaux, France.
- 2002-Now: INSERM Research Scientist. E362, U889, U1053, U1035 INSERM units, University of
Bordeaux, France.
Coordination:
- 2005 -2015: Scientific coordinator of the "microRNA and liver cancer" group.
-2016-2020: Scientific coordinator of the miRCaDe team (20 persons)
- Scientific coordinator of 3 multicentric projects (INCa PLBIO 2012, INCa TRANSLA 2013, FRM
BIOINFO 2013).
Organization of congresses:
- 2004: Fifth SifrARN meeting, Arcachon, France (www.ibgc.u-bordeaux2.fr/sifrarn/)
- 2010: 1st RNA and Cancer meeting, Cancéropôle Grand Sud-Ouest, Pessac, France.
- 2012: Génomique Fonctionnelle du Foie, Talence, France.
- 2008-2016: Bordeaux RNA Club (annual meeting), Pessac, France (www.iecb.u-bordeaux.fr/clubarn/
Club_ARN/Homepage.html)
Responsibilities, skills and expertise:
- Domain of expertise: Post-transcriptional regulation of genes, RNA-binding proteins, mRNA stability,
microRNA, hepatocellular carcinoma, hepatoblastoma, molecular and cellular biology, RNA seq.
- Major Committee Assignments:
- 2005, Member of the specialists’ commission, 65th section, University of Bordeaux, France
- 2004-2013, Member of the Master II degree’s commission, University of Bordeaux, France.
- 2010-2015, Thesis jury member (5).
- 2014-2015, Member of the Bordeaux University Academic and Research committees.
- Journal peer-reviewing: PNAS, Hepatology, Journal of Hepatology, British Journal of Cancer,
Carcinogenesis, Biochimie, International Journal of Cancer, European Journal of Cancer, BMC
Gastroenterology, PloS One, RNA, Nucleic Acids Research, Genome Biology, Clinics and Research in
Hepatology and Gastroenterology, Wiley Interdisciplinary Reviews: RNA, Vision Research, Molecular
and Cellular Probes, Médecine Sciences.
- Member of AFEF, ILCA, COG, SFBBM.
Grants and contract:
INCA, FRM, Cancéropôle Grand Sud-Ouest, La Ligue Nationale contre le Cancer, the University of
Bordeaux Excellence Initiative program, charity grants (Aidons Marina, ESCAPE, Eva pour la Vie,
Fondation Flavien, Fondation Groupama, Kaena et les Lapinours, Les Amis de Marius, Sphères),
Région Aquitaine.
Supervision and training:
2005-2016: 6 post-docs (3 ongoing), 5 PhD theses (2 ongoing; 2013 Monique Garnier-Semancik PhD
thesis Prize, Doctoral School, University of Bordeaux), 16 Pre-doctoral Diplomas, 4 Assistant
Engineers (3 ongoing).
Selected publications:
1. Laloo, B., D. Simon, V. Veilla, D. Lauzel, V. Guyonnet-Duperat, F. Moreau-Gaudry, F. Sagliocco,
and C. Grosset, Analysis of post-transcriptional regulations by a functional, integrated, and
quantitative method. Mol Cell Proteomics, 2009. 8(8): p. 1777-88.
2. Simon, D., Laloo, B., Barillot, M., Barnetche, T., Blanchard, C., Rooryck, C., Marche, M.,
Burgelin, I., Coupry, I., Chassaing, N., Gilbert-Dussardier, B., Lacombe, D., Grosset, C., and
Arveiler, B. A mutation in the 3'-UTR of the HDAC6 gene abolishing the post-transcriptional
regulation mediated by hsa-miR-433 is linked to a new form of dominant X-linked
chondrodysplasia, Hum Mol Genet, 2010, 19, 2015-2027.
3. Jalvy-Delvaille, S., M. Maurel, V. Majo, N. Pierre, S. Chabas, C. Combe, J. Rosenbaum, F.
Sagliocco, and C.F. Grosset, Molecular basis of differential target regulation by miR-96 and
miR-182: the Glypican-3 as a model. Nucleic Acids Res, 2012. 40(3): p. 1356-65.
4. Maurel, M., S. Jalvy, Y. Ladeiro, C. Combe, L. Vachet, F. Sagliocco, P. Bioulac-Sage, V. Pitard,
H. Jacquemin-Sablon, J. Zucman-Rossi, B. Laloo, and C.F. Grosset, A functional screening
identifies five microRNAs controlling glypican-3: role of miR-1271 down-regulation in
hepatocellular carcinoma. Hepatology, 2013. 57(1): p. 195-204.
5. Maurel, M., Dejeans, N., Taouji, S., Chevet, E. and Grosset, C.F. MicroRNA-1291-mediated
silencing of IRE1alpha enhances Glypican-3 expression. RNA, 2013. 19, 778-788.
Patenting:
1. Cartier, F., Lesjean, S., Sagliocco, F., and Grosset, C. (2015). Use of Glypican-3-targeting
microRNAs for treating liver cancer. European patent UNIVERSITE DE BORDEAUX-INSERM
n° 15 3061072; deposited on the 7th of July, 2015.
2. Indersie, E., Lesjean, S., Sagliocco, F., Buenda, M.-A., and Grosset, C. (2015). Use of cateninbeta 1-targeting microRNAs for treating liver cancer. European patent UNIVERSITE DE
BORDEAUX-INSERM-UNIVERSITE PARIS SUD - PARIS XI n° EP 15 3061130.